CHATSWORTH, Calif., May 25, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer, César M. García, will present an overview of the Company at the Jefferies Global Life Sciences Conference, June 8-11, 2010 at the Grand Hyatt Hotel in New York City. Mr. Garcia is scheduled to present on Thursday, June 10 at 3:00 p.m. Eastern Time, and will be available for one-on-one meetings with institutional investors at the conference throughout the day.
For those who are unable to attend, a live audio webcast may be accessed via the Investor's section of the IRIS website at http://www.proiris.com, or http://www.wsw.com/webcast/jeff46/iris/">http://www.wsw.com/webcast/jeff46/iris/. A replay will be archived on the Company's website for 90 days.
The Inaugural Jefferies Global Life Sciences Conference will feature presentations from more than 300 leading public and private healthcare companies across the life sciences spectrum, including biotechnology, life science tools, medical devices, diagnostics, specialty pharmaceuticals, and multi-national pharma. The four day conference will feature five concurrent tracks of company presentations, lunch panel discussions, a keynote presentation and investor meetings. For additional information, please contact your Jefferies sales representative, or visit http://www.jefferies.com.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,700 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA®, platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.